Back to Journals » Lung Cancer: Targets and Therapy » Volume 7

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer

Authors Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K

Received 9 November 2015

Accepted for publication 18 January 2016

Published 5 April 2016 Volume 2016:7 Pages 35—44

DOI https://doi.org/10.2147/LCTT.S100184

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Zhen Wang

Peer reviewer comments 4

Editor who approved publication: Prof. Dr. Pan-Chyr Yang

Seigo Minami, Yoshitaka Ogata, Shouichi Ihara, Suguru Yamamoto, Kiyoshi Komuta

Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan

Background: Small-cell lung cancer (SCLC) is responsive to initial chemotherapy but becomes resistant to cytotoxic drugs. The aim of this study was to evaluate what proportion of patients with SCLC had received the first- and further-line chemotherapy and which patients had benefited from chemotherapy.
Methods: We retrospectively reviewed medical records of patients with SCLC who had been treated with the best supportive care alone and the first-, second-, or third-line chemotherapy at the Osaka Police Hospital from June 2007 until March 2015.
Results: Among 145 patients diagnosed with SCLC and eligible for analysis, 118 patients received chemotherapy. We added five patients who initiated the second-line chemotherapy during the study period at our institution. Sixty-five and 31 patients received the second- and third-line chemotherapies, respectively. Multivariate logistic regression analysis detected age ≥75 years (odds ratio, 2.80; 95% confidence interval, 1.01–7.75; P=0.047) and European Clinical Oncology Group Performance Status (ECOG PS) 3–4 (14.3; 4.86–41.9; P<0.01) as factors disturbing the introduction of chemotherapy. Multivariate Cox hazard analyses also detected ECOG PS 2–4 (3.34; 2.00–5.58; P<0.01) as a factor decreasing overall survival after the first-line chemotherapy, and C-reactive protein level ≥1.0 mg/dL (2.67; 1.30–5.47; P<0.01) and progression-free survival after the first-line chemotherapy ≥6 months (2.85; 1.50–5.43; P<0.01) as factors influencing overall survival after the second-line chemotherapy.
Conclusion: Approximately two-thirds and one-third of the patients who receive chemotherapy proceed to the second- and third-line chemotherapies, respectively. Several factors, such as age, ECOG PS, C-reactive protein level, and progression-free survival after previous treatment may be useful when considering the introduction of further-line chemotherapy.

Keywords:
small-cell lung cancer, first-line chemotherapy, second-line chemotherapy, third-line chemotherapy, retrospective study, overall survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma

Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K

Lung Cancer: Targets and Therapy 2016, 7:99-110

Published Date: 24 August 2016

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study

Minami S, Ogata Y, Yamamoto S, Komuta K

Lung Cancer: Targets and Therapy 2015, 6:83-90

Published Date: 25 September 2015

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

Nishijima Y, Minami S, Yamamoto S, Ogata Y, Koba T, Futami S, Komuta K

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:439-444

Published Date: 27 February 2015

Readers of this article also read:

miRNA-21 as a novel therapeutic target in lung cancer

Markou A, Zavridou M, Lianidou ES

Lung Cancer: Targets and Therapy 2016, 7:19-27

Published Date: 2 March 2016

HSP90 as a novel molecular target in non-small-cell lung cancer

Esfahani K, Cohen V

Lung Cancer: Targets and Therapy 2016, 7:11-17

Published Date: 1 March 2016

Optimal delivery of male breast cancer follow-up care: improving outcomes

Ferzoco RM, Ruddy KJ

Breast Cancer: Targets and Therapy 2015, 7:371-379

Published Date: 23 November 2015

Clinical epidemiology of epithelial ovarian cancer in the UK

Doufekas K, Olaitan A

International Journal of Women's Health 2014, 6:537-545

Published Date: 23 May 2014

How to reduce your cancer risk: mechanisms and myths

Nahleh Z, Bhatti NS, Mal M

International Journal of General Medicine 2011, 4:277-287

Published Date: 8 April 2011

Capecitabine in the management of colorectal cancer

Hirsch BR, Zafar SY

Cancer Management and Research 2011, 3:79-89

Published Date: 24 March 2011